[go: up one dir, main page]

WO1998043643A1 - Preparations d'une solution aqueuse d'acyclovir - Google Patents

Preparations d'une solution aqueuse d'acyclovir Download PDF

Info

Publication number
WO1998043643A1
WO1998043643A1 PCT/JP1998/001340 JP9801340W WO9843643A1 WO 1998043643 A1 WO1998043643 A1 WO 1998043643A1 JP 9801340 W JP9801340 W JP 9801340W WO 9843643 A1 WO9843643 A1 WO 9843643A1
Authority
WO
WIPO (PCT)
Prior art keywords
acyclovir
aqueous solution
solution
boric acid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1998/001340
Other languages
English (en)
Japanese (ja)
Inventor
Mitsutoshi Kusumoto
Toshio Kasama
Mitsuru Noto
Susumu Oguro
Yuuki Nogami
Isao Hanazome
Tomoyuki Okamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TOA MEDICINE CO Ltd
Original Assignee
TOA MEDICINE CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOA MEDICINE CO Ltd filed Critical TOA MEDICINE CO Ltd
Publication of WO1998043643A1 publication Critical patent/WO1998043643A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • preservatives include parabens such as methylparaben, ethylparaben, and propylparaben; quaternary ammonium salts such as benzalkonium chloride and benzenetonium chloride; phenyl alcohol; chlorobutanol; and preferably parabens. Good to add.
  • acyclovir is used at a concentration of 0.1 to 3%, preferably 0.3 to 2%, more preferably 0.5 to 1.8%. And solubilized with at least one solubilizing agent selected from the group consisting of boric acid, and polyvinyl alcohol, hydroxyethyl cellulose, methylcellulose, or hydroxypropylmethylcellulose, and its pH is 3 to 9
  • the concentration of acyclovir is between 0.01 and 0.5%, preferably between 0.05 and 0.3%, more preferably between 0.05 and 0.2%. It is an aqueous solution, and polyvinylpyrrolidone is added to it.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des préparations d'une solution aqueuse d'acyclovir, agent antiviral fortement soluble dans des solutions aqueuses qui présentent une valeur de pH située autour de la neutralité et que l'on peut donc utiliser en tant que médicaments. Dans ces préparations la solubilité de l'acyclovir est maintenue à l'état d'une solution aqueuse stable. Ces préparations sont obtenues par la solubilisation d'acyclovir, opération réalisée grâce à l'utilisation d'acide borique et d'au moins un agent de solubilisation sélectionné à partir d'un alcool polyvinylique, d'hydroxyéthylcellulose, de méthylcellulose et d'hydroxypropylméthylcellulose ainsi que par la régulation de la valeur du pH de la solution aqueuse résultante entre 3 et 9. Ces préparations peuvent être utilisées en tant que collyres et gouttes nasales.
PCT/JP1998/001340 1997-04-01 1998-03-26 Preparations d'une solution aqueuse d'acyclovir Ceased WO1998043643A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9637797 1997-04-01
JP9/96377 1997-04-01

Publications (1)

Publication Number Publication Date
WO1998043643A1 true WO1998043643A1 (fr) 1998-10-08

Family

ID=14163282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/001340 Ceased WO1998043643A1 (fr) 1997-04-01 1998-03-26 Preparations d'une solution aqueuse d'acyclovir

Country Status (1)

Country Link
WO (1) WO1998043643A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011239A1 (fr) * 1997-09-03 1999-03-11 Chauvin Pharmaceuticals Limited Procede de preparation de compositions pharmaceutiques
JP2001278788A (ja) * 2000-03-30 2001-10-10 Zeria Pharmaceut Co Ltd アラントインを配合した安定な液剤
JP2002154989A (ja) * 2000-11-14 2002-05-28 Lion Corp 眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
WO2002064144A1 (fr) * 2001-02-16 2002-08-22 Nof Corporation Gouttes oculaires de suspension aqueuse et procede de production de celles-ci
WO2004000320A1 (fr) * 2002-06-24 2003-12-31 M's Science Corporation Preparation aqueuse de gouttes ophtalmique
JP2004196786A (ja) * 2002-12-03 2004-07-15 Taisho Pharmaceut Co Ltd 難溶性抗ウイルス成分含有水溶性外用剤組成物
JP2005008625A (ja) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd キノロン系抗菌化合物を含有する点眼液
JP2007500244A (ja) * 2003-06-13 2007-01-11 アルコン，インコーポレイテッド ２種のポリマーの相乗作用的組み合わせを含む眼科用組成物
US7709529B2 (en) 2002-08-01 2010-05-04 Eisai Inc. Treatment of cancer with glutamine
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4981524A (fr) * 1972-12-11 1974-08-06
JPS615018A (ja) * 1984-06-15 1986-01-10 Zeria Shinyaku Kogyo Kk 安定な点眼液
JPH03128320A (ja) * 1989-07-05 1991-05-31 Fujisawa Pharmaceut Co Ltd 水性外用液剤
JPH05186348A (ja) * 1991-03-27 1993-07-27 Takeda Chem Ind Ltd 水性懸濁液剤の製造法
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH08268892A (ja) * 1995-03-30 1996-10-15 Yuuwa Shoji:Kk 水溶液製剤及びその製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4981524A (fr) * 1972-12-11 1974-08-06
JPS615018A (ja) * 1984-06-15 1986-01-10 Zeria Shinyaku Kogyo Kk 安定な点眼液
JPH03128320A (ja) * 1989-07-05 1991-05-31 Fujisawa Pharmaceut Co Ltd 水性外用液剤
JPH05186348A (ja) * 1991-03-27 1993-07-27 Takeda Chem Ind Ltd 水性懸濁液剤の製造法
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH08268892A (ja) * 1995-03-30 1996-10-15 Yuuwa Shoji:Kk 水溶液製剤及びその製造方法

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741609B2 (en) * 1997-09-03 2001-12-06 Chauvin Pharmaceuticals Limited Method for preparing pharmaceutical formulations
GB2328872B (en) * 1997-09-03 2002-04-03 Chauvin Pharmaceuticals Ltd Method for preparing pharmaceutical formulations
US6379692B1 (en) 1997-09-03 2002-04-30 Chauvin Pharmaceuticals Limited Pharmaceutical composition comprising a suspension for the active ingredient
WO1999011239A1 (fr) * 1997-09-03 1999-03-11 Chauvin Pharmaceuticals Limited Procede de preparation de compositions pharmaceutiques
JP2001278788A (ja) * 2000-03-30 2001-10-10 Zeria Pharmaceut Co Ltd アラントインを配合した安定な液剤
JP2002154989A (ja) * 2000-11-14 2002-05-28 Lion Corp 眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
WO2002064144A1 (fr) * 2001-02-16 2002-08-22 Nof Corporation Gouttes oculaires de suspension aqueuse et procede de production de celles-ci
WO2004000320A1 (fr) * 2002-06-24 2003-12-31 M's Science Corporation Preparation aqueuse de gouttes ophtalmique
US7709529B2 (en) 2002-08-01 2010-05-04 Eisai Inc. Treatment of cancer with glutamine
JP2004196786A (ja) * 2002-12-03 2004-07-15 Taisho Pharmaceut Co Ltd 難溶性抗ウイルス成分含有水溶性外用剤組成物
JP2005008625A (ja) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd キノロン系抗菌化合物を含有する点眼液
JP2007500244A (ja) * 2003-06-13 2007-01-11 アルコン，インコーポレイテッド ２種のポリマーの相乗作用的組み合わせを含む眼科用組成物
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
JP2011184463A (ja) * 2003-06-13 2011-09-22 Alcon Inc ２種のポリマーの相乗作用的組み合わせを含む眼科用組成物
JP4860475B2 (ja) * 2003-06-13 2012-01-25 アルコン，インコーポレイテッド ２種のポリマーの相乗作用的組み合わせを含む眼科用組成物
US8313754B2 (en) 2003-06-13 2012-11-20 Novartis Ag Ophthalmic compositions containing a synergistic combination of two polymers

Similar Documents

Publication Publication Date Title
JP2769253B2 (ja) 水性液剤
US5589491A (en) Injection and injection kit containing omeprazole and its analogs
EP1225898B1 (fr) Compositions pharmaceutiques contenant un medicament antibiotique de fluoroquinolone et une gomme xanthan
JPS62123116A (ja) 水性液剤
KR910007511A (ko) 콜라겐 함유 안약 제형
WO1998043643A1 (fr) Preparations d'une solution aqueuse d'acyclovir
JP2916340B2 (ja) ナトリウムクロモグリケートの水性医薬組成物
CA3157999A1 (fr) Compositions injectables d'acide ursodesoxycholique
JPH0637388B2 (ja) 水性液剤
JPH06247872A (ja) 高濃度ｔｃｆ製剤
US5124152A (en) Parenteral formulation of metolazone
JPS63192714A (ja) 非経口用溶液
JP3720262B2 (ja) 安定化したカルベジロール注射溶液
KR20100014858A (ko) 국소 비강 투여용 올로파타딘 제제
KR102365008B1 (ko) 디쿠아포솔을 포함하는 점안 조성물
JPH1029937A (ja) メフェナム酸水溶液製剤
JP3213283B2 (ja) 注射剤
JPH05505813A (ja) ４―［２―（ベンゼンスルホニルアミノ）―エチル］―フェノキシ酢酸の医薬用水溶液
JP2001172183A (ja) 眼科用医薬組成物
JP4512700B2 (ja) アシクロビル含有水溶液製剤
JP4463206B2 (ja) グリチルリチン高濃度製剤
CA2010085C (fr) Solutions de pentamidine
JP2946015B2 (ja) 安定な抗ウィルス点滴用注射剤
JPH0383931A (ja) 低刺激性ｇｒｆ経鼻投与製剤
JPWO1998043643A1 (ja) アシクロビル水溶液製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase